ArticleJTO clinical and research reports2021

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors.

Samuel A Kareff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.